A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2022-06-25
AEs
3
Serious
1
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-07-19 (study day 18); relationship: not assessed
severe
serious
assessed
Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-09-03 (study day 64); relationship: N; serious criteria: life-threatening
mild
assessed
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-09-30 (study day 91); relationship: not assessed
Data queries
No data queries.